Introductory rate of $395 expires 2/28/10. Save $50 off the regular rate of $445. Click the sample link below to view the complete table of contents and select pages.

2009 ended similar to how the past decade started, as a flurry of big-time mergers and acquisitions swept through the upper echelon of the pharma world. The Pfizer/Wyeth, Roche/Genentech, and Merck/Schering-Plough combinations represented three of the top five deals across all global industry sectors in 2009, with the Pfizer/Wyeth transaction No. 1 overall. The wave of consolidation within various healthcare sectors will remain high during the beginning of the new decade as stressed companies that are licking wounds inflicted by the recent worldwide economic recession will be courted by corporations with strong cash flow and capital.

This special report analyzes the healthcare industry’s top 10 mergers and acquisitions during 2009, provides a comprehensive listing of healthcare companies’ M&A activity for last year, details the 2009 deals for the top 20 companies within each of the Pharmaceutical, Biotechnology, Specialty, and Medical Device sectors, and previews potential M&A activity within the healthcare arena for 2010.